All In Biotech

NDA 021995 · Msd

Januvia

Sitagliptin Phosphate · Oral

Novel

Last checked: Nov 19, 2026Latest source record: Dec 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2006

Oct 16, 2006

Approved uses

9

Original approval plus efficacy supplements

Registered trials

511

155 Phase 3, 14 recruiting

FAERS reports

72,446

46,797 serious, 6,838 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 8, 2026.

JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes ( 1 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1 , 5.1 ) Limitations of Use JANUVIA should not be used in patients with type 1 diabetes. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA. [See Warnings and Precautions (5.1) .]

Mechanism: Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • JANUVIA · SITAGLIPTIN PHOSPHATE EQ 50MG BASE · TABLET, ORAL · Prescription · TE AB
  • JANUVIA · SITAGLIPTIN PHOSPHATE EQ 100MG BASE · TABLET, ORAL · Prescription · TE AB
  • JANUVIA · SITAGLIPTIN PHOSPHATE EQ 25MG BASE · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Sitagliptin" as an intervention, any sponsor and status, largest first.

All 511 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased4,520
  • nausea3,964
  • diarrhoea3,630
  • drug ineffective3,575
  • fatigue3,003
  • headache2,582
  • dizziness2,508
  • vomiting2,462
  • dyspnoea2,402
  • acute kidney injury2,283
  • pancreatitis2,231
  • death2,218

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200627
20073,569
20082,411
20092,444
20101,757
20111,967
20122,836
20133,661
20144,463
20156,599
20165,273
20174,741
20185,086
20195,057
20204,557
20213,805
20223,621
20232,891
20242,851
20252,804
20262,026

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Januvia (Sitagliptin Phosphate)

2024 spending

$3.81B

Beneficiaries

828,288

4,027,317 claims

Per beneficiary

$4,597

$17.97 per unit

View as table
YearSpending
2020$3,865,087,773
2021$4,059,534,112
2022$4,097,997,365
2023$4,090,836,821
2024$3,807,854,662

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 742 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.